New Launch24 Feb 2025, 10:28 pm
Biocon Biologics Launches Yesintek™, a Stelara® Biosimilar, in the US
AI Summary
Biocon Biologics Ltd. has announced the launch of Yesintek™ (ustekinumab-kfce), a biosimilar to Stelara® (ustekinumab), in the United States. Yesintek™ is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, increasing patient access to more cost-effective treatment options for common chronic autoimmune diseases. The biosimilar will be available in all the same formulations currently provided by Stelara®. Biocon Biologics is excited to be among the first companies to introduce a high-quality, affordable biosimilar Ustekinumab to patients in the US.
Key Highlights
- Biocon Biologics launches Yesintek™, a Stelara® biosimilar, in the US
- Yesintek™ is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
- Yesintek™ will be available in all the same formulations currently provided by Stelara®
- Biocon Biologics is among the first companies to introduce a high-quality, affordable biosimilar Ustekinumab to patients in the US
- Yesintek™ offers a seamless treatment experience covering the same indications and dosing options as Stelara®